SNOA Sonoma Pharmaceuticals, Inc.: Price-to-Projected Revenue Ratio

Global logistics disruptions and sanctions are limiting the export of Sonoma Pharmaceuticals (SNOA) antiseptics to foreign markets. Business revenues rely on the implementation of Microcyn in dentistry and retail. Effective cost control by management has stabilized operational activities. The expected P/S ratio demonstrates the valuation trend relative to revenue forecasts, where the value 0.20 represents the current metric.
Metric breakdowns and analytics for Sonoma Pharma (SNOA)

The forward P/S reflects the market value of the business relative to expected sales volume, allowing investors to assess the degree of overpayment for the asset in real time. By analyzing the projected P/S of Sonoma Pharmaceuticals (SNOA), one can identify risks of undervaluation or asset overheating amid regulatory barriers and component supply disruptions that impact the revenue scalability of the pharmaceutical business.